JP2015517511A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517511A5
JP2015517511A5 JP2015512051A JP2015512051A JP2015517511A5 JP 2015517511 A5 JP2015517511 A5 JP 2015517511A5 JP 2015512051 A JP2015512051 A JP 2015512051A JP 2015512051 A JP2015512051 A JP 2015512051A JP 2015517511 A5 JP2015517511 A5 JP 2015517511A5
Authority
JP
Japan
Prior art keywords
antibody
kit
seq
lymphoma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517511A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/060098 external-priority patent/WO2013171287A1/en
Publication of JP2015517511A publication Critical patent/JP2015517511A/ja
Publication of JP2015517511A5 publication Critical patent/JP2015517511A5/ja
Pending legal-status Critical Current

Links

JP2015512051A 2012-05-16 2013-05-15 Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用 Pending JP2015517511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12168398 2012-05-16
EP12168398.1 2012-05-16
PCT/EP2013/060098 WO2013171287A1 (en) 2012-05-16 2013-05-15 Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)

Publications (2)

Publication Number Publication Date
JP2015517511A JP2015517511A (ja) 2015-06-22
JP2015517511A5 true JP2015517511A5 (enExample) 2016-06-30

Family

ID=48463997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512051A Pending JP2015517511A (ja) 2012-05-16 2013-05-15 Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用

Country Status (4)

Country Link
US (1) US8992915B2 (enExample)
EP (1) EP2849784A1 (enExample)
JP (1) JP2015517511A (enExample)
WO (1) WO2013171287A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
KR102706161B1 (ko) * 2017-03-31 2024-09-19 젠맵 홀딩 비.브이. 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
DE68929167T2 (de) 1988-09-06 2000-11-16 Xoma Corp., Berkeley Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
EP2295468B1 (en) 2002-02-14 2015-07-08 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6596757B1 (en) 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
EP1534336A4 (en) * 2002-08-15 2005-12-14 Human Genome Sciences Inc ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
SI1912675T1 (sl) * 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
EP2167130A2 (en) 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
SG189772A1 (en) * 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP6049163B2 (ja) * 2008-07-21 2016-12-21 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 改善された治療上の特徴のための抗体の構造変異体
BRPI0921006A2 (pt) * 2008-11-13 2015-12-15 Emergent Product Dev Seattle terapias imunoterapêuticas combinadas de cd37 e usos destas
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
JP2015516980A (ja) 2012-04-26 2015-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とベンダムスチンとの併用
EP2849783A1 (en) 2012-05-16 2015-03-25 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with further agents

Similar Documents

Publication Publication Date Title
JP2015517511A5 (enExample)
Melamed et al. Multiple sclerosis and cancer: the ying-yang effect of disease modifying therapies
JP2017507954A5 (enExample)
TWI818120B (zh) 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療
JP2015517512A5 (enExample)
JP2010529026A5 (enExample)
JP2019517549A5 (enExample)
JP6917681B2 (ja) 腫瘍性疾患のための治療
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
JP2015516980A5 (enExample)
JP2013511975A5 (enExample)
JP2017537927A5 (enExample)
KR20240117655A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
US20180319861A1 (en) Combination therapy for malignant diseases
AU2014227019A1 (en) Novel peptide having 5 linked CTL epitopes
JP2018522881A5 (enExample)
TW201834650A (zh) 哺乳類雷帕黴素靶蛋白抑制劑及氯喹於治療癌症之用途
JP7504106B2 (ja) がんの処置のための組合せ物
JP2015500836A5 (enExample)
US20250114456A1 (en) Enhanced immunotherapeutic method comprising combined administration of photodynamic / radiotherapeutic compounds and immunotherapeutic agents
US20250381190A1 (en) Therapeutic combinations of capivasertib and venetoclax
CN112543637B (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途
CA2464947C (en) Combination therapy for treating disease